{"id":233426,"date":"2026-03-16T22:13:27","date_gmt":"2026-03-17T03:13:27","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/03\/adjuvant-randomized-controlled-trial-rationale-and-design"},"modified":"2026-03-16T22:13:27","modified_gmt":"2026-03-17T03:13:27","slug":"adjuvant-randomized-controlled-trial-rationale-and-design","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/03\/adjuvant-randomized-controlled-trial-rationale-and-design","title":{"rendered":"ADJUVANT Randomized Controlled Trial: Rationale and Design"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/adjuvant-randomized-controlled-trial-rationale-and-design2.jpg\"><\/a><\/p>\n<p>ADJUVANT: Testing if IV tirofiban is non-inferior to thrombolysis before endovascular thrombectomy for acute ischemic stroke. Read about the upcoming trial.<\/p>\n<hr>\n<p>BackgroundIntravenous thrombolysis followed by endovascular thrombectomy (EVT) is a first\u2010line recommended strategy for thrombolysis\u2010eligible patients with stroke due to acute large\u2010vessel occlusion. Tirofiban, one of the most used glycoprotein IIb\/IIIa receptor inhibitors, has been increasingly advocated to counteract different stages of thrombosis mediated by activated platelets. It is unclear whether tirofiban could be used as an alternative to thrombolysis as adjuvant medicine for EVT. This trial aims to assess whether intravenous tirofiban plus EVT is noninferior to intravenous thrombolysis bridging with EVT in patients with acute ischemic stroke due to large\u2010vessel occlusion who are eligible for thrombolysis.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ADJUVANT: Testing if IV tirofiban is non-inferior to thrombolysis before endovascular thrombectomy for acute ischemic stroke. Read about the upcoming trial. BackgroundIntravenous thrombolysis followed by endovascular thrombectomy (EVT) is a first\u2010line recommended strategy for thrombolysis\u2010eligible patients with stroke due to acute large\u2010vessel occlusion. Tirofiban, one of the most used glycoprotein IIb\/IIIa receptor inhibitors, has been [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-233426","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/233426","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=233426"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/233426\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=233426"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=233426"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=233426"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}